<DOC>
	<DOCNO>NCT01273493</DOCNO>
	<brief_summary>The purpose study characterize pharmacokinetics ( blood level ) trabectedin administration patient advanced malignancy hepatic ( liver ) dysfunction .</brief_summary>
	<brief_title>A Pharmacokinetic Study Trabectedin Patients With Advanced Malignancies Hepatic Dysfunction</brief_title>
	<detailed_description>This open-label ( patient know name study drug receive ) , single-dose , study examine pharmacokinetics ( blood level ) ass survival safety trabectedin patient advanced malignancy either hepatic ( liver ) dysfunction hepatic dysfunction ( patient enrol without hepatic dysfunction refer control group ) . Trabectedin drug develop treat patient cancer administer intravenously ( i.v . ) catheter ( tube ) central vein . In addition , dexamethasone , drug use prevent nausea vomit chemotherapy patient may protective effect liver , administer patient administration trabectedin . Patients complete treatment phase study opinion investigator would derive overall clinical benefit treatment trabectedin opportunity continue treatment trabectedin optional extension phase . The dose schedule trabectedin may modify treat physician optional extension phase appropriate type malignancy treat . A single dose trabectedin ( 1.3 mg/m2 patient control group 0.58 mg/m2 patient hepatic dysfunction ) administer i.v.infusion 3-hour period . The dose trabectedin may adjust necessary patient hepatic dysfunction subsequently enrol study . All patient administer dexamethasone 20 mg i.v . ( equivalent ) approximately 30 minute administration trabectedin .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Trabectedin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients locally advance metastatic disease , solid tumor except hepatocellular carcinoma , previously treat systemic chemotherapy ( chemotherapy administer blood ) relapse progressive disease follow standard care treatment chemotherapy prior enrollment , intolerant prior standard care treatment chemotherapy Patients Eastern Cooperative Oncology Group ( ECOG ) score &lt; =2 time screen Patients enrol hepatic dysfunction must laboratory test result total bilirubin &gt; 1.5x &lt; =3x upper limit normal ( ULN ) liver function test ( alanine aminotransferase [ ALT ] aspartate aminotransferase [ AST ] ) &lt; 8x ULN Patients enrol without hepatic dysfunction must laboratory test result total bilirubin less ULN , alkaline phosphatase ( ALP ) &lt; =1.5x ULN , AST ALT &lt; =the ULN . Patients previous exposure trabectedin Patients know liver disease Patients diagnose hepatocellular carcinoma , history biliary sepsis within past 2 year Patients unwilling central catheter In hepatic dysfunction group , patient hepatic dysfunction Gilbert 's syndrome . Patients sign encephalopathy ( altered brain function ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Trabectedin , YONDELIS</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Locally advanced metastatic disease</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Hepatic Dysfunction</keyword>
</DOC>